ONCOCROSS

CONTACT US
CONTACT US

History

Through integration with OncoMaster, connecting expanded medical services

Oncocross's key milestones reflect advances in technology, business expansion, partnerships, and clinical progress, as well as the story of business expansion through integration with OncoMaster.

You can see how our business portfolio has expanded from an existing AI-based drug discovery platform to multi-omics, data assetization, diagnostics, and patient-specific precision medicine services.

2 0 2 6
2026
    2026.4.
    Decision made to merge with and absorb oncoMASTER Co., Ltd.
    2026.1.
    KRW 20 billion investment in Omix AI Co., Ltd.,(proteomics analysis company)
2025
    2025.12.
    Chung-Ang University Hospital – Joint Business Agreement on AI-Based Digital Biobanking
    2025.10.
    Chonnam National University Hwasun Hospital - Research collaboration on AI-driven future medicine
    2025.10.
    Aptis - National project on AI-based next-generation ADC therapeutics development
    2025.09.
    ARSACS Foundation - Collaboration with Université Laval (Canada) – Rare Disease Drug Development Project
    2025.07.
    Research Collaboration with Variational AI Inc. (Canada)
    2025.06.
    Research Collaboration on Drug Development with Seoul National University Hospital
2024
    2024.12.
    Listed on the KOSDAQ Market
    2024.09.
    Obtained Pre-Approval of KOSDAQ Listing Application
    2024.07.
    Drug Evaluation Service with Kine Science on peptide asset
    2024.04.
    Drug Evaluation Service with JW Pharmaceutical – indication expansion of 3 drugs under development
2023
    2023.11.
    Pre-IPO Funding Closed (KRW 14.5 billion) – includes SI investment from DONGWHA Pharm
    2023.07.
    Obtained Technical Evaluation ‘A’ rating from both NICE Information Service and Korea Planning & Evaluation Institute of Industrial Technology
    2023.03.
    Completed Global Phase I Clinical Trials of OC514 (Treatment for Sarcopenia)
    2023.03.
    Research Collaboration with Boryung – Indication Expansion of KANARB
2022
    2022.12.
    Awarded "2022 Outstanding Enterprise for Work-Life Balance” by City of Seoul
    2022.12.
    Awarded "Good AI Awards 2022"
    2022.10.
    Research Collaboration with AlphaMol Science(Switzerland)
    2022.09.
    MOU with Gachon University Gil Medical Center
    2022.07.
    Yirang Kim, CEO of Oncocross, appointed as the 1st Chairman of ‘AI Drug Development Council’ under the auspice of KPBMA
    2022.03.
    Research Collaboration with JW Pharmaceutical
    2022.01.
    Research Collaboration on Anti-Cancer Drug with Donghwa Pharmaceutical
2021
    2021.12.
    Obtained the 'Technical Evaluation' for Public Listing
    2021.11.
    Anti-Metastasis (OC210/202e) IIT begin (Asan Medical Center, Severance Hospital, Haeundae Paik Hospital) 해운대백병원)
    2021.10.
    Selected TOP10 for 'GO AUSTRIA' Program, organized by Austria Wirtschaftsservice Gesellschaft mbH (AWS)
    2021.10.
    Research Collaboration on Scleroderma with 4P Pharma of Institut Pasteur de Lille
    2021.10.
    3rd place in China Chongqing Innovation and Entrepreneurship Roadshow Contest
    2021.09.
    ONCOfind AI IIT begin (Kangbuk Samsung Hospital, National Cancer Center)
    2021.06.
    Selected in Skydeck Accelerator, UC Berkeley
    2021.06.
    Obtained Technical Evaluation 'A' rating from Korea Technology Finance Corp (KIBO)
    2021.06.
    Established ONCOCROSS AUSTRALIA Pyt Ltd.
    2021.05.
    Research Collaboration with Columbia University Medical Center
    2021.04.
    Research Collaboration with Cyclica Inc.
    2021.04.
    MOU with HLB on Anti-Cancer Drug Development
    2021.04.
    MOU with Choong Nam University on AI Drug Discovery Research Collaboration
    2021.04.
    MOU with CHA Bundang Medical Center
    2021.04.
    Research Collaboration with Samsung Medical Center
    2021.03.
    Research Collaboration with / SI Investment from Daewoong Pharmaceutical
2020
    2020.12.
    Awarded the 'Best SME Company' for this year from Money Today
    2020.12.
    Awarded the 'Best Entrepreneur' from the Ministry of SMEs and Startups, Government of Korea
    2020.09.
    Research Collaboration with ST Pharm on COVID-19 & Dengue Fever
    2020.09.
    Selected as 'BIG3 R&D' Project with COVID-19 & Infectious Disease
    2020.08.
    Series B Funding Closed (KRW 16.5 billion)
    2020.08.
    MTA with Cancer Research UK
    2020.06.
    OC514 (sarcopenia treatment) License-Out to Korea Pharma
    2020.06.
    Selected as 'TIPS' Business
    2020.05.
    Selected in the Government Sponsored 'Growth Jump' Package
    2020.05.
    Selected as 'SMEs' BIG3 Innovative Growth' Project
    2020.02.
    MOU with Seoul National University on PharmDB-K Research
    2020.01.
    CDA with MD Anderson on Sarcopenia Treatment
    2020.01.
    JPI-289 License-In from Jeil Pharmaceutical
2019
    2019.10.
    Awarded from Ministry of Health and Welfare, Government of Korea
    2019.09.
    Optimal Indication and Biomarker Screening Service for ST Pharm
    2019.07.
    Selected as 'IP Voucher' Business
    2019.05.
    Series A Funding Closed (KRW 6 billion)
2018
    2018.11.
    Selected as TIPS
    2018.10.
    Selected in the Government Sponsored 'Growth Jump' Package
    2018.10.
    MOU with Korea Research Institute of Chemical Technology
2017
    2017.04.
    Selected in the Government Sponsored Cancer Project
2016
    2016.04.
    Obtained 'Venture Company' Status
2015
    2015.08.
    Obtained Research Laboratory Status
    2015.06.
    Established ONCOCROSS CO., LTD,